

**Merchant & Gould**

An Intellectual Property Law Firm

3200 IDS Center  
80 South Eighth Street  
Minneapolis, Minnesota  
55402-2215 USA  
TEL 612.332.5300  
FAX 612.332.9081  
www.merchant-  
gould.com

**RECEIVED  
CENTRAL FAX CENTER****NOV 03 2004**

A Professional Corporation

**Fax Transmission** | November 3, 2004

TO: Commissioner for Patents  
Attn: Examiner Aniruddho Ray Chaudhuri  
P.O. Box 1450  
Alexandria, VA 22313-1450

FROM: Katherine M. Kowalchuk

OUR REF: 11669.147USU1  
TELEPHONE: 612.371.5311

Total pages, including cover letter: **4**PTO FAX NUMBER 1-703.872.9306

If you do NOT receive all of the pages, please telephone us at 612.371.5204, or fax us at 612.332.9081.

Title of Document Transmitted:

RESPONSE TO RESTRICTION  
REQUIREMENT AND PETITION FOR  
EXTENSION OF TIME:

Applicant: CHUNTHARAPAI ET AL.  
Serial No.: 10/044,896  
Filed: JANUARY 9, 2002  
Group Art Unit: 1644  
Our Ref. No.: 11669.147USU1  
Confirmation No. 1225

Please charge our Deposit Account No. 13-2725 in the amount of \$110.00 for one-month extension of time fee. Please charge any additional fees or credit overpayment to Deposit Account No. 13-2725. Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate.

By: Katherine M. Kowalchuk  
Name: Katherine M. Kowalchuk  
Reg. No.: 36,848

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on the date shown below.

Sheryl A. Boerboom

Sheryl A. Boerboom  
Signature

November 3, 2004  
Date

GEN033.DOT

S/N 10/044,896

PATENTIN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	CHUNTHARAPAI ET AL.	Examiner:	A. CHAUDHURI
Serial No.:	10/044,896	Group Art Unit:	1644
Filed:	JANUARY 9, 2002	Docket No.:	11669.147USU1
Confirmation No.:	1225	Customer No.:	23552
Title:	ANTI-INTERFERON-ALPHA ANTIBODIES		

CERTIFICATE UNDER 37 CFR 1.6(d):

I hereby certify that this paper is being transmitted by facsimile to the U.S. Patent and Trademark Office on November 3, 2004.

By:   
Name: Sheryl A. Boerboom

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This paper is being filed in response to the restriction requirement dated September 20, 2004.

While not acquiescing to any of the statements of the Examiner, Applicants elect the subject matter of Group I, claims 1-30 and 42-48 with traverse. Applicants further elect antibody V13 which comprises light chain sequence comprising SEQ ID NO:3 and heavy chain sequence comprising SEQ ID NO:5. A vector encoding a heavy chain comprising SEQ ID NO:5 is deposited as PTA-2881 with ATCC. A vector encoding a light chain comprising SEQ ID NO:3 is deposited as PTA-2882 with ATCC. The elected claims readable on the elected species are 1, 3, 5-29, 41-42 and 44-48.

Applicants traverse the restriction requirement. Applicants submit that the Examiner has not established it would be unduly burdensome to search the subject matter of claim 49 (Group IV) and/or claims 50-54 (Group V). Applicants submit that the subject matter of these claims is found in the same class as that of the Group I claims. Moreover, a search of the antibodies is

likely to include information directed to methods of using the antibodies. Thus, Applicants request that the Examiner search claim 49 and/or claims 50-54.

If the Examiner does decide to also search and examine claims 49-54, Applicants elect systemic lupus erythematosus.

**INTERVIEW SUMMARY**

Applicants thank the Examiner for the interview on November 2, 2004. We discussed that the search should include antibodies to all IFN $\alpha$  subtypes.

Examination on the merits is requested.

Respectfully submitted,

MERCHANT & GOULD P.C.  
P.O. Box 2903  
Minneapolis, Minnesota 55402-0903  
(612) 332-5300

Dated: November 3, 2004 By Katherine M. Kowalchyk  
Katherine M. Kowalchyk  
Reg. No. 36,848  
KMK:sab

